Skip to Content

Risk Factors for JAK-Inhibitor Treatment in Atopic Dermatitis

Ida Vittrup, MD and PhD, Department of Dermatology, Bispebjerg Hospital, Denmark, discusses a cross-sectional study on risk factors, presented at EADV 2023, that could affect the use of JAK-inhibitors in Danish patients with atopic dermatitis. The results reveal the prevalence of various risk factors among the patient population and how they influence the choice of JAK-inhibitor treatment.

Ida Vittrup

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top